ArticleMolecular genetics and genomics : MGG2026
Cannabidiol (CBD) differentially shapes systemic cytokines and transcriptomic profiles in the liver and spleen: insights from a male mouse model.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cannabidiol (CBD) is widely studied for its anti-inflammatory and immunomodulatory properties, yet its relationship with systemic cytokine responses and organ-level transcriptional changes remains incompletely defined. Here, we investigated the dose- and time-dependent effects of CBD on circulating pro-inflammatory cytokines and the transcriptomic profiles of the liver and spleen in male C57BL/6J mice. Animals received CBD intraperitoneally at 0.2, 10, or 20 mg/kg body weight for either 2 days (short-term, ST) or 28 days (long-term, LT), with vehicle-treated controls. Serum IL-1β, IL-6, and TNF-α were measured by ELISA, and RNA-Seq was performed on liver and spleen to characterize differential gene expression and enriched biological processes. CBD significantly reduced IL-1β and TNF-α after ST treatment across doses, whereas IL-6 decreased primarily during LT exposure, with the strongest reduction at day 14 and partial persistence to day 28 at higher doses. Transcriptomic responses were markedly organ- and regimen-dependent. The liver transcriptome exhibited pronounced, dose- and time-dependent remodeling, with the largest number of differentially expressed genes at 20 mg/kg in ST and broad changes across doses in LT. The gene enrichment analyses indicated modulation of mitochondrial and translational pathways after ST high-dose exposure, lipid and fatty acid metabolism during LT, as well as circadian-associated regulation at higher-dose LT treatment, with innate immune-associated signaling terms enriched at the highest dose. In contrast, the spleen displayed comparatively modest transcriptional changes, with limited differential expression in LT and a clearer response only after ST exposure to 20 mg/kg, where altered genes showed trends related to lipid-associated processes. Together, these findings demonstrate that CBD attenuates circulating pro-inflammatory cytokines while inducing strong, dose- and time-dependent hepatic transcriptional reprogramming and relatively limited splenic transcriptomic shifts. The integration of systemic and organ-specific data supports a model in which CBD acts as a systemic immunometabolic modulator rather than a simple immunosuppressant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.